[go: up one dir, main page]

TW318850B - - Google Patents

Download PDF

Info

Publication number
TW318850B
TW318850B TW084111436A TW84111436A TW318850B TW 318850 B TW318850 B TW 318850B TW 084111436 A TW084111436 A TW 084111436A TW 84111436 A TW84111436 A TW 84111436A TW 318850 B TW318850 B TW 318850B
Authority
TW
Taiwan
Prior art keywords
aryl
alkyl
group
hydrogen
compound
Prior art date
Application number
TW084111436A
Other languages
English (en)
Inventor
Louis Plamondon
Original Assignee
Proscript Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26987313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW318850(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Proscript Inc filed Critical Proscript Inc
Application granted granted Critical
Publication of TW318850B publication Critical patent/TW318850B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)

Description

318850 A8 B8 C8 D8 々、申請專利範圍 c6_10芳基、c6_10芳（Ci-6)烷基、Ch6烷（c6_1〇)芳基或雜環中 之任一者之環部分可選擇性地經取代；且 (請先閱讀背面之注意事項再填寫本頁) A係0、1或2。 3 ·如申請專利範圍第2項之化合物，其中： p係r7-c(o)-或r7-so2-，其中R7係喹啉基、喹噁啉基 、吡啶基、吡嗪基、呋喃基或吡咯基中之一者，或當P係 R7-C(0)時，R7亦可係N-嗎啉基。 4·如申請專利範圍第2項之化合物，其中p係喹啉擬基 、口比D定鑛基、喹啉礦驢基、喹B惡琳鐵基、D奎H惡琳礦酿基、D比嗪 羰基、吡嗪磺醯基、呋喃羰基、呋喃磺醯基或N-嗎啉羰基中 之一者。 5·如申請專利範圍第4項之化合物，其中P係8_喹啉羰 基、8-喹啉磺醯基、2-喹噁啉羰基、2-喹噁啉磺醯基、2-吡嗪 羰基、2-吡嗪磺醯基、3-呋喃羰基、3-呋喃磺醯基或N-嗎啉 鑛基中之一者。 6.如申請專利範圍第2項之化合物，其中A係〇。 7·如申請專利範圍第2項之化合物，其中R係氫或Cl_8 烷基。 經濟部智慧財產局員工消費合作社印製 8.如申請專利範圍第2項之化合物，其中： R2係氫、C!-8烷基、C3_1G環烷基、C6-1G芳基、5_、6-、9-或10-節雜芳基、或-CH2_R5中之一者； R5 係 C6.1G 芳基、C6-10 芳（Ci-6)院基、Ci_6院（C6_10)芳基 、C3-IG環院基、Ci_8院氧基、Ci-8院硫基或5-、6-、9 -或 10-節雜芳基中之一者； 其中R2及R5之該芳基、芳烷基、烷芳基或5-、6-、9- 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐）-4 - 318850 A8 B8 C8 D8 六、申請專利範圍 (請先閱·#背面之注意事項再填寫本頁) 或10-節雜芳基中任一者之環部分可視情況經一個或兩個各 選自烷基、C3_8環烷基、Cu烷基（C3.8)環烷基、（:2_8 烯基、C2_8炔基、氰基、胺基、c!_6烷胺基、二（(^_6)烷胺 基、苄胺基、二苄胺基、硝基、羧基、羰基（<^_6)烷氧基、 三氟甲基、鹵素、Cb6烷氧基、c6_1()芳基、C6_1()芳（Ci.6)烷 基、C6_1G芳（Ci-6)院氧基、經基、Ci_6院硫基、Ci_6院亞礦 醯基、Ch6烷磺醯基、C6_1G芳硫基、C6_1G芳亞磺醯、c6_10 芳磺醯基、C6_1G芳基、Cu烷基（c6_1G)芳基及鹵基（c6_1G)芳 基中之取代基所取代。 9·如申請專利範圍第2項之化合物，其中R3係異丁基 〇 10. 如申請專利範圍第2項之化合物，其中R2係異丁基 、2-萘甲基、3-哦啶甲基、2-吼啶甲基、6-喹啉甲基、3-D引D朵 甲基、苄基、4-氟苄基、4-羥苄基、4-(2，-吡啶甲氧）苄基、 4-(苄氧）苄基、苄萘甲基或苯乙基中之一者。 11. 如申請專利範圍第2項之化合物，其中Z1及Z2各係 ◦ 1- 6^71：基、經基或Ci_6院氧基中之一*者。 經濟部智慧財產局員工消費合作社印製 12. 如申請專利範圍第n項之化合物，其中Ζι及z2皆 係羥基。 13·如申請專利範圍第2項之化合物，其中Z1及Z2 —起 形成由選自噸那醇（pinacol )、全氟噸哪醇、蒎烷二醇、乙 二醇、二伸乙基二醇、1，2 -環己烷二醇、1，3 -丙二醇、2 ，3-丁二醇、甘油或二乙醇胺中之二羥基化合物所衍生之部 分。 14.如申請專利範圍第2項之化合物，其中該化合物係 本&張尺度逋用中國國家襟準（CNS ) A4規格（210X297公釐）_ 5 - ' 318850 A8 B8 C8 D8 經濟部智慧財產局員工消費合作社印製 六、申請專利範圍 下列者之一： N-(2-吡嗪）羰基-L-苯基丙胺酸-L-白胺酸腿酸， N-(2-喹啉）磺醯-L-高苯基丙胺酸-L-白胺酸臓酸， N-(3-吡啶）羰基-L-苯基丙胺酸-L·白胺酸腿酸， N-(4-嗎啉）羰基-L-苯基丙胺酸-L-白胺酸画酸， N-(4-嗎啉）羰基·β·(1_萘基）-L-丙胺酸-L-白胺酸腿酸， N-(8-喹啉）磺醯-β-(1-萘基）-L-丙胺酸-L-白胺酸願酸， N-(4-嗎啉）羰基-(0-苄基）-L-酪胺酸-L-白胺酸哪酸， N-(4-嗎啉）羰基-L-酪胺酸-L·白胺酸臓酸， N - (4 -嗎啉）碳基-〔0 · (2 -卩比D定甲基）〕-L -酪胺酸-L -白胺酸願酸 ， 或其藥學上可接受之鹽。 1 5 .如申請專利範圍第1 4項之化合物，其中該化合物係 N-(2-吡嗉）羰基-L-苯基丙胺基-L-白胺酸腿酸。 16·如申請專利範圍第1項之化合物，其中 P爲氫或胺基保護部份； R2爲萘甲基，吡啶甲基或喹啉甲基； A爲0，1或2。 17·如申請專利範圍第16項之化合物，其中p係r7_ c(o)-、r7_so2-、r7-nh-c(o)-或 r7-o-c(o)_，且 R7係C6-10芳基、C6_10#(Ci-6)院基、5-至10-節雜芳基 或5-至10-節雜芳（Cl_6)烷基中之一者，其中任一者皆可視 情況經取代，或當P係R7-C(0)-時，R7亦可係N_嗎啉基。 1 8 ·如申請專利範圍第1 7項之化合物，其中P係 R7-C(0)-或 r7_s〇2-;且 本紙張尺度適用中國國家襟準（CNS ) A4規格（210X297公釐）-6 - . 訂 (請先閱讀背面之注意事項再填寫本頁) 318850 A8 B8 C8 D8 六、申請專利範圍 (請先閱讀背面之注意事項再填寫本頁) R係C6_l〇芳基、C6-10方（Ci_6)院基、5 -至10 -節雜芳基 或5-至10-節雜芳基（Chd烷基，其中任一者皆可視情況經 取代，或當P係R7-C(0)-時，R7亦可係N-嗎啉基。 19.如申請專利範圍第16項之化合物，其中A係零。 2 0 .如申請專利範圍第1 6項之化合物，其中R2係喹啉甲 基。 21·如申請專利範圍第16項之化合物，其中該化合物係 下述者之一： N-(4-嗎啉）羰基-β-(1-萘基）-L-丙胺酸-L-白胺酸腦酸，或 N-(8-喹啉）磺醯基- β-(1-萘基）-L-丙胺酸-L-白胺酸腿酸。 22·如申請專利範圍第1項之化合物，其中 P爲氫或胺基保護基部分； R與R2 —起形成含氮之單-、雙-、或三-環、飽和或部 分飽和之具有4 -1 4個ig自卩之纟哀系統，其可選擇性經一*個或 兩個酮基、羥基、C!_8烷基、C6-1Q芳基、C6_1G芳（Ci-6)烷基 、（：丨_8烷氧基或C6_1()芳氧基所取代； R3爲氮、Ci-8院基、或-CH2_(C6-1Q)芳基； A爲0 〇 經濟部智慧財產局員工消費合作社印製 23 .如申請專利範圍第.22項之化合物，其中該含氮之環 系統係選自下列者： 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐）-7 - 318850 六 A8 B8 C8 D8 、申請專刊範圍
R -c(0)、、R7-S〇2-、R7-nh-c(〇)-或 R7-0-C(0)_，且 •如申請專利範圍第2 2項之化合物，其中p係 (請先閲讀背面之注意事項再填寫本頁) \ 、τ Γ R係C6-i〇芳基、c6-i〇芳（Ci-6)烷基、5-至10-節雜芳基 或 5 _革 1 if. 一 1〇、節雜芳（<^_6)烷基中之一者，其中任一者皆可視情 況糸111取代’或當P係R7-C(0)_時，R7亦可係N-嗎啉基。 經濟部智慧財產局員工消費合作社印製 25 ·如申請專利範圍第24項之化合物，其中p係 R _e⑼·或 H7-S〇2-;且 尺7係C11Q芳基、C6_1Q芳（Ci-6)烷基、5-至10-節雜芳基 或5_至1(K節雜芳基（Cl_6)烷基中之一者，其中任一者皆可 視情況經取代，或當P係R7-C(0)-時，R7亦可係N-嗎啉基 〇 26·如申請專利範圍第22項之化合物，其中P係氫。 27·如申請專利範圍第22項之化合物，其中該化合物係 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐）-8 - 318850 A8 B8 C8 D8 六、申請專利範圍 L-脯胺酸-L-白胺酸腿酸。 (請先閱讀背面之注意事項再填寫本頁) 28.如申請專利範圍第1項之化合物，其中 P爲氫或胺基保護基部分； R1各係氫或烷基； R2係：
其中R9係氫、烷基、環烷基、芳基、芳烷基、雜芳基或雜 芳烷基中之一者，其中烷基視情況經CU6烷基、鹵素、單鹵 基（C!·6)烷基、及三氟甲基中之一者所取代； 經濟部智慧財產局員工消費合作社印製 且其中該環烷基、芳基、芳烷基、雜芳基及雜芳基烷基可視 情況經一個或兩個Cu烷基、C3_8環烷基、Cl 6烷基（c3_8) 環院基、C2-8儲基、C2-8炔基、氰基、胺基、Ci-6院胺基、 二（CL6)烷胺基、苄胺基、二苄胺基、硝基、羧基、羰基（ Ci-6)垸氧基、三氟甲基、鹵素、Cl-6垸氧基、C6-10芳基、 C6-1G芳基（Cl-6)院基、C6-10方基（Ci_6)院氧基、經基、Ci_6 烷硫基、Ci_6烷亞磺醯基、¢^6烷磺醯基、C6_1G芳硫基、 C6_10芳亞磺醯基、C5-1()芳磺醯基、C6-10芳基、Cu烷基 (C6_1G)芳基、及鹵基（C6_1G)芳基所取代； A1及A2各係氫、鹵素、Cu烷基、單鹵基（Cm)烷基， 或三氟甲基中之一者； A係0、1或2。 本紙張尺度適用中國國家標準（CNS ) A4規格(210X297公釐）_ 一 ^ 318850 A8 B8 C8 D8 六、申請專利範圍 29·如申請專利範圍第28項之化合物，其中p係 R7-C(0)、、r7_s〇2_、r7_nh-C(0)-或 R7-0-C(0)_，且 (請先閱讀背面之注意事項再填寫本頁) R係C6_1G芳基、C6_1G芳（Cb6)烷基、5_至1〇-節雜芳基 或5-至10-節雜芳（C^)烷基中之一者，其中任一者皆可視 ^況經取代，或當p係R7-C(0)-時，R7亦可係N-嗎啉基。 3 〇·如申請專利範圍第29項之化合物，其中p係 r7-c(〇)1 r7-S02-;且 R係C6_1G芳基、C6.1G芳（Ci-6)烷基、5 -至10 -節雜芳基 或5_至10-節雜芳基（(^_0)烷基，其中任一者皆可視情況經 取代’或當P係R7-C(0)-時，R7亦可係1嗎啉基。 3 1·如申請專利範圍第28項之化合物，其中R2係 其中 A1及A2各係氫、Cl_6烷基、鹵素、單鹵基（Ci6)烷基或 三氟甲基中之一者； 經濟部智慧財產局員工消費合作社印製 R9係Cu烷基、c3_1G環烷基、Cn。芳基、C6_1G芳（ C!-6)烷基、5-至10-節雜芳基或5-至10-節雜芳基（Cl_6)院基 中之~'者。 32·如申請專利範圍第28項之化合物，其中A係零。 3 3 ·如申請專利範圍第2 8項之化合物，其中該化合物係： Ν-(4·嗎啉）羰基-(0-苄基）-L-酪胺酸-L-白胺酸酸， N-(4-嗎啉）羰基-L-酪胺酸-L-白胺酸腿酸，或 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐）-1〇_ 318850 經濟部智慧財產局員工消費合作社印製 A8 B8 C8 D8 々、申請專利範圍 N-(4-嗎啉）羰基-〔〇-(2-吡啶甲基）〕-L-酪胺酸-L-白胺酸腿酸 〇 34.—種具下式之化合物： γΐο_Ν_χ13_ H R13 (2a) 及其藥學上可接受之鹽； 其中 Y 係 r8-c(o)-、r8-so2-、r8_nh-c(0)-或 R8-0-C(0)-中 之一者，其中R8係Cu烷基、Cn❹芳基、Cu烷（C6_1())芳 基、C6_1()芳（Chd烷基中之一者，其中任一者可視情況經取 代，或當γ係r8-c(o)-或r8_so2-，貝ϋ r8亦可係視情況經 取代之5至1 0節飽和、部分不飽和或芳族雜環； X13係共價鍵結或-c(0)-ch2-; R13 係氣、Ci_8 院基、-CH2-(C6-1Q)方基； Z1及Z2各係Cb8烷基、羥基、或（^_8烷氧基、或一起 形成由具有至少兩個被至少兩個鏈中或環中聯結原子所分隔 之羥基的二羥基化合物，該鏈或環包含碳原子及選擇性之氮 原子； 先決條件係當Y係R8-C(0)-時，R8不爲苯基、苄基或 Ci-Cs烷基。 3 5 ·如申請專利範圍第3 4項之化合物，其中γ 1 0係 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐）-11 - (請先閱讀背面之注意事項再填寫本頁)
中之一者’其中R4係C6-12烷基。 3 6 . —種具下式之化合物： Y—N—X3—CH—B^XZ2) H R3 (2a) 及其藥學上可接受之鹽； 其中 Y是 p—CHj-CH—C-—; I II r1 o (3a)
P 係 R7-C(0)-、R7-S02-、R7-NH-C(0)-或 R7-〇-C
I I n I I n I — I n I I I I ^ (請先閱p背面之注意事項再填寫本頁J 經濟部智慧財產局員工消費合作社印製 (〇)中 之一者，其中 &7係Cb8烷基、C6_1()芳基、Cb6烷（c6_1G)芳基、 C6-1G芳（c^6)烷基中之一者，其中任一者可視情況經取代， 或當Y係R7-C(0)-或R7-S〇2_時，R7亦可係視情況經取代之 5至1 0節飽和、部分不飽和或芳族雜環； X3係共價鍵結或-c(o)-ch2-; R1各係氫、Ci-8垸基、C3_1()環院基、c6_1G芳基、5至 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐）-12 - 争 318850 A8 B8 C8 D8 六、申請專利範圍 (請先閱,背面之注意事項再填寫本頁) 10節飽和、部分不飽和或芳族雜環或-CH5中之〜者， 其中’該芳基或雜環中任一者之環部分可選擇性地經取代； R3係氫、Cu烷基、c3_1G環烷基、c6_1G芳基、5至10 節飽和、部分不飽和或芳族雜環或-CH5中之一者，其中 該芳基或雜環中之任一者可選擇性地經取代； R5各係c6·!。芳基、Ch。芳（Cu)院基、Cu烷（c6_1Q)芳 基，C3_1G環烷基、5至10節飽和、部分飽和或芳族雜環或 -W-R6中之一者，其中W係硫屬且尺6係Ci_8烷基，其中該 C6-1()芳基、C6_IG芳（Cu)烷基、Cl_6烷（C6_1())芳基或雜環中 之任一者之環部分可選擇性地經取代；且 Z1及Z2各係Ci-8烷基、羥基、Cl_8烷氧基中之一者， 或Z1及Z2 —起形成由具有至少兩個被至少兩個鏈中或環中 之聯結原子分隔之羥基的二羥基化合物所衍生之部分，該鏈 或環包含碳原子及選擇性之氮原子。 3 7 ·如申請專利範圍第3 6項之化合物，其中Y係 經濟部智慧財產局員工消費合作社印製
0〇 _ 3 8 · —種用於抑制哺乳類蛋白酶體功能之藥學組合物， 其包含如申請專利範圍第1或34或36項之化合物及其藥學 上可接受之載體或稀釋劑。 39.如申請專利範圍第38項之藥學組合物，其中該化合 物之存在量係可有效地抑制晡乳類體內之蛋白酶體功能。 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐）-13 - 318850 A8 B8 C8 D8 六、申請專利範圍 40.—種抑制癌細胞生長之藥學組成物，其包括可有效 抑制生長之量之如申請專利範圍第1或34或36項之化合物 〇 4 1 . 一種降低細胞內肌肉蛋白降解速率之藥學組成物， 其包括有效量之具下式之蛋白酶體抑制劑： pio 一n—B11-X11 R10 R11 CH——X12 —CH——B(Z11)(Z12) R12 R13 A10 (lb) (請先閱讀背面之注意事項再填寫本頁)
或其藥學上可接受之鹽 其中 p1 ^係氫或胺基保護部分； B11，各係 CH ; X11，各係-C(〇)-NH-; X12 係-C(0)-NH-; R1Q係氫或C"烷基，或當係零時，與相鄰R!2 一 起形成含氮之單-、雙-或三環、飽和或部分飽和之具有4-14 個環節之環系統，其可選擇性經一個或兩個酮基、趣基、 C!_8烷基、。芳基、。芳（Ci_6)烷基、Cl_8烷氧基或 C 6 - 1 0芳氧基所取代； R11各係氫或C! _8烷基； R12係氫、C"烷基、c3_1G環烷基、C6_1G芳基、5、1〇節 飽和、部分不飽和或芳族雜環或_CH2_r15中之一者，其中該 C6-1Q芳基、或雜環中任—者之環部分可選擇性地經取 本紙張尺度適用中國國家標準（CNS ) A4規格（21〇χ297公董）_ 14 訂 争 經濟部智慧財產局員工消費合作社印製 A8 B8 C8 D8 318850 六、申請專利範圍 R13 係氫、Ci_8 院基、或- CH2-(C6_1())芳基； R15 各係 C6_1G 芳基、C6-1G 芳（CU6)烷基、Ci 6 院（(^ 〕 芳基、C3 _ 1 〇環院基、5 -1 0節飽和、邰分飽和或芳族雜環戌 _w1g-r16中之一者，其中w1G係硫屬且尺“係Ci 8烷基，其 中該C6_l〇芳基、C6-l〇芳（Ci_6)烷基、Cu烷（C6_1〇)芳基或雜 環中之任一者之環部分可選擇性地經取代； Z11及Z12各係C!·8烷基、羥基、或山_8烷氧基中之〜 者，或Z11及Z12 —起形成由具有至少兩個被至少兩個鏈中 或環中之聯結原子分隔之羥基的二羥基化合物所衍生之部分 ，該鏈或環包含碳原子及任意之氮原子；且 A1G 係 0、1 或 2。 42.—種降低細胞內NF-kB( nuclear factor-kB，核因子 k Β)活性之藥學組成物，其包括有效量之下式蛋白酶體抑制 劑·· 1 -I «n n_i ml —^ϋ ml an n I ^^1 i (請先閱讀背面之注意事項再填寫本頁} pio—ν—Β11—X11 I R11 ·—CH—X12—CH—Β(Ζ11)(Ζ12】R12 R13 Α10 ⑽ 争 經濟部智慧財產局員工消費合作社印製 或其藥學上可接受之鹽； 其中 Ριυ係氫或胺基保護部分； Β11，各係 CH ; X11，各係-C(0)-NH-; X12 係-C(0)-NH-; 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐）-15 - 318850 A8 B8 C8 D8 經濟部智慧財產局員工消費合作社印製 夂、申請專利範圍 R1()係氫或Cm烷基，或當A1()係零時，與相鄰Rl2s 起形成含氮之單-、雙-或三環、飽和或部分飽和之具有4-i4 個環節之環系統，其可選擇性經一個或兩個酮基、羥基、 Cl-8院基、C6_10芳基、C6_10芳（Ci-6)院基、Ci-8院氧基或 C 6 _ ! 〇芳氧基所取代； R11各係氯或Ci_8院基； R12係氫、C"烷基、c3_1G環烷基、C6_1G芳基、5-10節 飽和、部分不飽和或芳族雜環或-CHpR15中之一者，其中 該C6_1G芳基、或雜環中任一者之環部分可選擇性地經取代 R13 係氫、Ci-8 院基、或- CH2-(C6-1G)芳基； R15 各係 c6_10 芳基、c6_10 芳（Cu)烷基、Cb6 烷（C6-10) 芳基、〇環烷基、5-10節飽和、部分飽和或芳族雜環或 -W1G-R16中之一者，其中W1G係硫屬且R16係Ch烷基， 其中該Cnc芳基、C6_1()芳（Cm)烷基、Cu烷（C6_1G)芳基或 雜環中之任一者之環部分可選擇性地經取代； Z11及Z12各係山_8烷基、羥基、或Cu烷氧基中之一 者，或Z11及Z12 —起形成由具有至少兩個被至少兩個鏈中 或環中之聯結原子分隔之羥基的二羥基化合物所衍生之部分 ，該鏈或環包含碳原子及任意之氮原子；且 A10 係 〇、1 或 2。 43. —種降低細胞內蛋白質破壞之藥學組成物，其包括 有效量之下式蛋白酶體抑制劑： 财關緖準（CNS ) A4· ( 210X297公釐）_ 16 · ^ 、訂 I ^^1 (請先閎讀背面之注意事項再填、寫本頁j 318850 A8 B8 C8 D8 六、申請專利範圍 p10-N一 I R10 B11—X”「CH—χη—CH—Β(Ζ11)02) R11 A10 (lb) 經濟部智慧財產局員工消費合作社印製 或其藥學上可接受之鹽； 其中 p1()係氫或胺基保護部分； B11，各係 CH ; X11，各係-C(0)-NH-; X12 係-C(0)-NH-; R1G係氫或CU8烷基，或當A1G係零時，與相鄰R 起形成含氮之單-、雙-或三環、飽和或部分飽和之具有4-14 個環節之環系統，其可選擇性經一個或兩個酮基、羥基、 Cb8烷基、。芳基、C“1()芳（Cl_6)烷基、Cm烷氧基或 C6-10芳氧基所取代； R11各係氫或C!_8烷基； R12係氫、Cm烷基、C3-1G環烷基、C6_1()芳基、5-10節 飽和、部分不飽和或芳族雜環或- CH2_R15中之一者，其中該 C6_1Q芳基、或雜環中任一者之環部分可選擇性地經取代； R13係氫、Ch烷基、或-ch2-(c6_1())芳基； R 各係 C6_1G 芳基、C6-10 芳（Ci_6)院基、C1-6 院（06 ι〇) 方基、C3 _ i 〇 ί哀烷基、5 -1 0節飽和、部分飽和或芳族雜環或 -W1G-R16中之一者，其中wi〇係硫屬且Rl6係I 8烷其， 其中該。芳基、c6.1()芳（Cl_6)烷基、〇16烷（(^芳基或 雜環中之任一者之環部分可選擇性地經取代； & 1 2 (請先閱讀背面之注意事項再填寫本頁) 318850 A8 B8 C8 D8 、申請專利範圍 Z11及Z12各係Cu烷基、羥基、或Cl.8烷氧基中之一 者，或Z11及Z12 —起形成由具有至少兩個被至少兩個鏈中 或環中之聯結原子分隔之羥基的二羥基化合物所衍生之部分 ，該鏈或環包含碳原子及任意之氮原子；且 A10 係 0、1 或 2。 44· 一種降低細胞內p53蛋白質（tumor suppressor protein p53，腫瘤抑制劑蛋白質p53)之降解速率的藥學組成 物，其包括有效量之下式蛋白酶體抑制劑： (請先閱讀背面之注意事項再填寫本頁) pio—n—
I R10 B11——X11
I R11 CH—
I
Ri2 A10 (lb)
B 經濟部智慧財產局員工消費合作社印製 或其藥學上可接受之鹽； 其中 p1 ^係氫或胺基保護部分； 各係CH ; X11，各係-C(0)-NH-; X12 係-C(0)-NH-; R1G係氫或Cu烷基，或當A1G係零時，與相鄰R12 — 起形成含氮之單-、雙-或三環、飽和或部分飽和之具有 個環節之環系統，其可選擇性經一個或兩個酮基、羥基、 Cu院基、C6_1G芳基、c6_1G芳（Cy)烷基、c!_8烷氧基或 c 6 · 1 0芳氧基所取代； R11各係氫或Cu烷基； 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐）_ 18 _ 318850 A8 B8 C8 D8 、申請專利範圍 R12係氫、匕_8烷基、c3_1G環烷基、c6_1G芳基、5-10節 飽和、部分不飽和或芳族雜環或_CH2_R15中之—者，其中 該C6_1G芳基、或雜環中任一者之環部分可選擇性地經取代 R13係氫、烷基、或_CH2-(C6 lQ)芳基； R15 各係 c6_1()芳基、c6“。芳（Cl 6)院基、Ci 6 烷（c6 i〇) 方基、C3 _ 1 〇環烷基、5 -1 0節飽和、部分飽和或芳族雜環或 -W1G-R16中之一者，其中wl〇係硫屬且r16係Ci_8烷基， 其中該Cno芳基、C6-1()芳（CU6)烷基、Cu烷（c6_1())芳基或 雜環中之任一者之環部分可選擇性地經取代； Z11及Z12各係Ci_8烷基、羥基、或Ci_8烷氧基中之一 者，或Z11及Z12 —起形成由具有至少兩個被至少兩個鏈中 或環中之聯結原子分隔之羥基的二羥基化合物所衍生之部分 ’該鏈或環包含碳原子及任意之氮原子；且 A1 υ 係 0、1 或 2。 45.—種抑制細胞內塞克林（eyelin )降解之藥學組成物 其包括有效量之下式蛋白酶體抑制劑” (請先閱讀背面之注意事項再填寫本頁) 訂- 經濟部智慧財產局員工消費合作社印製 ρΐο_μ—rB11—X11I I R10 R11 CH—X12 —CH—日) A10 (lb) 或其藥學上可接受之鹽； 其中 P1()係氫或胺基保護部分； 本紙張尺度適用中國國家襟準（〇奶）八4規格（210/297公釐）-19- 318850 A8 B8 C8 D8 六、申請專利範圍 B11，各係 CH ; X11，各係-C(0)-NH-; (請先閱讀背面之注意事項再填寫本頁) X12 係-C(0)-NH-; R1()係氫或（^_8烷基，或當係零時，與相鄰R!2 一 起形成含氮之單-、雙-或三環、飽和或部分飽和之具有4_14 個壤卽之ί哀系統，其可選擇性經一個或兩個酮基、羥基、 Ci-8烷基、C6_1G芳基、Ch。芳（Cu)烷基、Cl_8烷氧基或 C 6 _ i 〇芳氧基所取代； R11各係氫或Cm烷基； R1 2係氫、C 1 · 8烷基、c 3 _】〇環烷基、C 6 _ i 〇芳基、5 -1 0節 飽和、部分不飽和或芳族雜環或-CHyR15中之一者，其中該 C 6 · 1 〇芳基、或雜環中任一者之環部分可選擇性地經取代； R13係氫、c"烷基、或-ch2-(c6-1g)芳基； 經濟部智慧財產局員工消費合作社印製 R15 各係 c6_10 芳基、C6_10 芳（Ci_6)院基、Ci_6 烷（C6_10) 芳基、Cm環烷基、5-10節飽和、部分飽和或芳族雜環或 -Wig-r16中之一者，其中wlG係硫屬且Rl6係Ci 8烷基， 其中該c6_1()芳基、c6_1()芳（Ci-6)烷基、Cu烷（c6_1())芳基或 雜環中之任一者之環部分可選擇性地經取代； Z11及Z12各係山-8烷基、羥基、或Cl_8烷氧基中之一 者’或Z11及Z12 —起形成由具有至少兩個被至少兩個鏈中 或環中之聯結原子分隔之羥基的二羥基化合物所衍生之部分 ，該鏈或環包含碳原子及任意之氮原子；且 A1Q 係 0、1 或 2。 4 6. —種預防或治療需治療患者之發炎狀況的藥學組成 本紙張尺度適用中國國家襟準（CNS ) A4規格（210X297公釐）-20 · 318850 A8 B8 C8 D8 六、申請專利範圍 物，其包括有效量之下式蛋白酶體抑制劑 pio—N—B11——X11 R10 R11 —CH—X12—CH—B(211)(Z12) R12 R13 A10 (lb) 或其藥學上可接受之鹽； 其中 P1()係氫或胺基保護部分
B 各係CH ; (請先閱讀背面之注意事項再填寫本頁} 經濟部智慧財產局員工消費合作社印製 X11，各係-C(0)-NH-; X12 係-C(0)-NH-; R1Q係氫或烷基，或當A1G係零時，與相鄰_ 起形成含氮之單-、雙-或三環、飽和或部分飽和之具有4_14 個環節之環系統，其可選擇性經一個或兩個酮基、翔基、 Ci-8院基、C6-1G芳基、C6-1。芳（Ci_6)院基、Ci-8院氧基戌 c6-1G芳氧基所取代； R11各係氫或Ch烷基； R12係氫、c"烷基、Cn。環烷基、c6_1G芳基、5·1〇節 飽和、部分不飽和或芳族雜環或-CH2_R15中之一者，其中該 C 6 -1 0方基、或雜環中任一者之環部分可選擇性地經取代； R 係氣、C1-8院基、或-CH2-(C6-ig)方基； R15各係C6_1G芳基、C6·〗。芳（Cm)烷基、Cu烷（c 八 V L 6 - 1 〇 ) 芳基、C3_1G環烷基、5-1〇節飽和、部分飽和或芳族雜環或 -W1G_r16中之一者，其中wlG係硫屬且^6係Ci_8烷基，其 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐）-21 318850 A8 B8 C8 D8 六、申請專利範圍 中該c6_10芳基、C6_10芳（Ci-6)院基、Ci_6院（c6_10)芳基或雜 環中之任一者之環部分可選擇性地經取代； Z11及Z12各係Cl_8烷基、羥基、或Cl_8烷氧基中之一 者’或Z11及Z12 —起形成由具有至少兩個被至少兩個鏈中 或環中之聯結原子分隔之羥基的二羥基化合物所衍生之部分 ，該鏈或環包含碳原子及任意之氮原子；且 A1C)係 〇、1 或 2。 47.如申請專利範圍第46項之藥學組成物，其中該患者 係經診斷具有選自組織排斥、器官排斥、關節炎、感染、皮 膚病、發炎性腸疾、及自體免疫疾病中之狀況或發展彼者之 危險。 4 8.—種抑制細胞內抗原表現之藥學組成物，其包括有 效量之下式蛋白酶體抑制劑： P10_N_B11_X11_CH—_CH—B(Z11)(Zi2) R10 R” fU R13 • JA10 或其藥學上可接受之鹽； 其中 P1()係氫或胺基保護部分； B11，各係 CH ; X11，各係-C(0)-NH-; X12 係-C(0)-NH-; R1 0係氫或C ! _ 8烷基，或當A 1G係零時，與相鄰R12 — 起形成含氮之單-、雙-或三環、飽和或部分飽和之具有4_14 本紙張尺度適用中國國家標準（〇灿）八4規格（210父297公釐）_22- (請先閱讀背面之注意事項再填寫本頁) 訂 (lb) 經濟部智慧財產局員工消費合作社印製 318850 A8 B8 C8 D8 經濟部智慧財產局員工消費合作社印製 六、申請專利範圍 個環節之環系統，其可選擇性經一個或兩個酮基、經基、 CU8院基、Cq。芳基、。芳（Cl_6)烷基、Cl_8烷氧基或 c 6 - 1 Q芳氧基所取代； R11各係氫或6_8烷基； R 係氫、C1-8院基、C3-1()環院基、C6-10芳基、5-10節 飽和、部分不飽和或芳族雜環或-CH^R15中之一者，其中該 C6_1Q芳基、或雜環中任一者之環部分可選擇性地經取代； R13 係氫、CU8 烷基、或-CH2-(C6_1())芳基； R15 各係 C6_1G 芳基、C6_1G 芳（Cm)烷基、Cu6 烷（CVl〇) 芳基、C3_1()環烷基、5-10節飽和、部分飽和或芳族雜環或 -Wi、Rl6中之一者，其中wlG係硫屬且Rl6係山_8烷基，其 中該C6-1G芳基、C6_1()芳（Cm)烷基、Cu烷（C6-1G)芳基或雜 環中之任一者之環部分可選擇性地經取代； Z11及Z12各係Cm烷基、羥基、或Cu烷氧基中之一 者，或Z11及Z12 —起形成由具有至少兩個被至少兩個鏈中 或環中之聯結原子分隔之羥基的二羥基化合物所衍生之部分 ，該鏈或環包含碳原子及任意之氮原子；且 A1G 係 0、1 或 2。 49·一種於需該抑制之動物體內抑制可誘發之與NF-kB 有關之細胞黏連的藥學組成物，其包括有效量之下式蛋白酶 體抑制劑： pio一N—B11一X11I I R1〇 R11 CH—X12—CH—B(Z11)(Z^) R12 R13 (lb) 本紙張尺度適用中國國家襟準（CNS ) A4規格（21〇Χ297公釐）-23 - (請先閲讀背面之注意事項再填寫本頁) 訂- 參· A8 B8 C8 D8 318850 六、申請專利範圍 或其藥學上可接受之鹽； 其中 p 1""係氫或胺基保護部分； B11，各係 CH ; X"，各係-C(0)-NH-; X12 係-C(0)-NH-;
RlG係氫或Cu烷基，或當A1G係零時，與相鄰R12 — 起形成含氮之單-、雙-或三環、飽和或部分飽和之具有4 個環節之環系統，其可選擇性經一個或兩個酮基、殘基、 Ci-8院基、C6-10芳基、C6-10芳（Ci-6)院基、Ci-8院氧基或 C6-1()芳氧基所取代； RU各係氫或Ci.8烷基； R12係氫、Cm烷基、C3_1G環烷基、C6-1G芳基、5_1〇節 飽和、部分不飽和或芳族雜環或-CHrR15中之一者，其中該 C6-1G芳基、或雜環中任一者之環部分可選擇性地經取代；
Ri3係氫、Cu烷基、或-CH2-(C6_1())芳基； R15 各係 c6.1()芳基、c6·!。芳（Ci_6)院基、Cu 院（c 、 八 V L 6 · 1 〇 ) 芳基、C^o環烷基、5-10節飽和、部分飽和或芳族雜環或 -W1()-R16中之一者，其中W1G係硫屬且R!6係Cu8烷基，其 中該c6_1()芳基、c6_1()芳（Ci_6)院基、CU6院（c6_1())芳基或雜 環中之任一者之環部分可選擇性地經取代； Z11及Z12各係Cl_8烷基、羥基、或Cl_8烷氧基中之一 者，或Z11及Z12 —起形成由具有至少兩個被至少兩個鏈中 或環中之聯結原子分隔之羥基的二羥基化合物所衍生之部分 本紙張尺度適用中國國家標準（CNS ) Α4規格（210X297公釐）· 24 - (請先閱讀背面之注意事項再填寫本頁)
、1T 經濟部智慧財產局員工消費合作社印製 318850 A8 B8 C8 D8 、申請專利範圍 ，該鍵或ί哀包含碳原子及任意之氣原子，且 A1G 係 0、1 或 2。 50· —種於需要該抑制之動物體內抑制 HIV(human immunodeficiency virus，人類免疫缺乏症病毒）複製之藥學 組成物，其包括有效量之下式蛋白酶體抑制劑： pio —N- R10 B11—χ11 I R” ，CH—X12—CH—B(Z11)(Z12) R13 A10 (lb) (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 I紙張尺度適用中國國家標準（CNS) Α4· ( 210x297公羡)乂 25 一 或其藥學上可接受之鹽； 其中 p1 ^係氫或胺基保護部分； B11，各係 CH ; X11，各係-C(0)-NH-; X12 係-C(0)-NH-; R1G係氫或Cy烷基，或當A1()係零時，與相鄰Ru — 起形成含氮之單-、雙·或三環、飽和或部分飽和之具有4_14 個環節之環系統，其可選擇性經一個或兩個酮基、羥基、 Cl-8 it兀基、C6-10芳基、C6-10芳（Ci_6)院基、Ci_8院氧基戌 C 6 - ! 〇芳氧基所取代； R11各係氫或（^_8烷基； R12係氫、C"烷基、c3.1()環烷基、c6_1()芳基、5_1〇節 飽和、部分不飽和或芳族雜環或_CH2-R15中之一者，其中琴 芳基、或雜環中任一者之環部分可選擇性地經 318850 A8 B8 C8 D8 六、申請專利範圍 R13係氫、Cb8烷基、或-CH2-(C6.1Q)芳基； (請先閱讀背面之注意事項再填寫本頁) R15各係C6-1G芳基、C6_i〇芳（Cm)烷基、Cl_6院彳^⑼) 芳基、c3 _ i 0環烷基、5 -1 G節飽和、部分飽和或芳族雜環或 _w1g-r16中之一者，其中w1G係硫屬且尺“係Ci8烷基，其 中該C6_10芳基、C6_10芳（Cu)烷基、Cb6烷（c6_10)芳基或雜 環中之任一者之環部分可選擇性地經取代； Z11及Z12各係Cm烷基、羥基、或Cl_8烷氧基中之一 者，或Z11及Z12 —起形成由具有至少兩個被至少兩個鏈中 或環中之聯結原子分隔之經基的二經基化合物所衍生之部分 ，該鏈或環包含碳原子及任意之氮原子；且 A10 係 0、1 或 2。 51.如申請專利範圍第 40、41、42、43、44、45、46、 48、49及50項中任一項之藥學組成物，其中該蛋白酶體抑 制劑係下述者之一： N-(2-吡嗪）羰基苯基丙胺酸-L-白胺酸腿酸， N-(2-喹啉）磺醯-L-高苯基丙胺酸-L-白胺酸腿酸， N-(3-吡啶）羰基-L-苯基丙胺酸-L-白胺酸硼酸， 經濟部智慧財產局員工消費合作社印製 N - (4 -嗎琳）鑛基-L -苯基丙胺酸-L -白胺酸腿酸’ N-(4-嗎啉）羰基-β-(1-萘基）-L-丙胺酸-L-白胺酸腦酸， N-(8-喹啉）磺醯-β-(1-萘基）-L-丙胺酸-L-白胺酸哪酸’ N-(4-嗎啉）羰基-(〇-苄基）-L-酪胺酸-L-白胺酸哪酸， N-(4-嗎啉）羰基-L-酪胺酸-L-白胺酸硼酸，或 N-(4-嗎啉）羰基-〔0-(2-吡啶甲基）〕-L-酪胺酸-L-白胺酸鹏酸 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐）_ 26 - 318850 A8 B8 C8 D8 々、申請專利範圍 5 2.—種降低細胞內肌肉蛋白質降解速率之藥學組成 物，其包括有效量之如申請專利範圍第34或36項之化合物 (請先閲讀背面之注意事項再填寫本頁) 〇 5 3.—種降低細胞內NF-kB活性之藥學組成物，其包括 有效量之如申請專利範圍第34或36項之化合物。 5 4. —種降低細胞內蛋白質破壞速率之藥學組成物，其 包括有效量之如申請專利範圍第34或36項之化合物。 55.—種降低細胞內p53蛋白質降解速率的藥學組成物 ，其包括有效量之如申請專利範圍第34或36項之化合物。 56·—種抑制細胞內塞克林（cyclin )降解之藥學組成物 ，其包括有效量之如申請專利範圍第3 4或3 6項之化合物。 5 7.—種於需治療之患者體內預防或治療發炎狀況之藥 學組成物，包括有效量之如申請專利範圍第34或36項之化 合物。 經濟部智慧財產局員工消費合作社印製 58.如申請專利範圍第57項之藥學組成物，其中該患者 係經診斷具有選自組織排斥、器官排斥、關節炎、感染、皮 膚炎、發炎性腸疾、氣喘、骨質疏鬆症、骨關節炎及自體免 疫疾病中之狀況或有發展彼者之危險。 5 9.—種抑制癌細胞生長之藥學組成物，其包括有效量 之如申請專利範圍第34或36項之化合物。 60. —種抑制細胞內抗原表現之藥學組成物，其包括有 效量之如申請專利範圍第34或36項之化合物。 6 1.—種抑制動物體內與NF-kB有關之細胞粘連的藥學 組成物，其包括有效量之如申請專利範圍第34或36項之化 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐）_ 27 - 318850 as C8 D8 六、申請專利範圍 合物。 62.—種抑制動物體內之HIV複製的藥學組成物，其包 括有效量之如申請專利範圍第3 4或3 6項之化合物。 (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準（CNS ) A4規格（210X297公釐）-28 -
TW084111436A 1994-10-28 1995-10-27 TW318850B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33052594A 1994-10-28 1994-10-28
US08/442,581 US6083903A (en) 1994-10-28 1995-05-16 Boronic ester and acid compounds, synthesis and uses

Publications (1)

Publication Number Publication Date
TW318850B true TW318850B (zh) 1997-11-01

Family

ID=26987313

Family Applications (1)

Application Number Title Priority Date Filing Date
TW084111436A TW318850B (zh) 1994-10-28 1995-10-27

Country Status (24)

Country Link
US (16) US6083903A (zh)
EP (4) EP0788360B3 (zh)
JP (1) JP3717934B2 (zh)
KR (1) KR100398944B1 (zh)
CN (2) CN1305475C (zh)
AT (3) ATE314378T1 (zh)
AU (1) AU710564B2 (zh)
CA (2) CA2203936C (zh)
CH (1) CH0788360H1 (zh)
CY (1) CY2484B1 (zh)
DE (5) DE122004000025I1 (zh)
DK (3) DK1312609T3 (zh)
ES (3) ES2254803T3 (zh)
FI (2) FI114801B (zh)
FR (1) FR04C0014I2 (zh)
IL (5) IL115790A (zh)
LU (1) LU91083I2 (zh)
MX (1) MX9703063A (zh)
NL (1) NL300151I2 (zh)
NO (2) NO310558B1 (zh)
NZ (2) NZ337211A (zh)
PT (3) PT788360E (zh)
TW (1) TW318850B (zh)
WO (1) WO1996013266A1 (zh)

Families Citing this family (307)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6838477B2 (en) * 1995-04-12 2005-01-04 President And Fellows Of Harvard College Lactacystin analogs
FR2758329B1 (fr) * 1997-01-16 1999-02-12 Synthelabo Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
US6271199B2 (en) 1997-02-15 2001-08-07 Millennium Pharmaceuticals, Inc. Treatment of infarcts
US6221888B1 (en) * 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
WO1999015183A1 (en) * 1997-09-25 1999-04-01 Proscript Inc. PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-λB VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES
CN1163594C (zh) * 1997-09-29 2004-08-25 尖端医疗有限公司 体外造血细胞的刺激
US6831057B2 (en) * 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
CA2219867A1 (en) * 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
DE19802450A1 (de) * 1998-01-23 1999-07-29 Hoechst Marion Roussel De Gmbh Ustilipide, Verfahren zu deren Herstellung sowie deren Verwendung
US6075150A (en) * 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
US6838436B1 (en) * 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6902721B1 (en) * 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) * 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6979697B1 (en) * 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
EP0982317A1 (en) * 1998-08-26 2000-03-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalent inhibitors of the proteasome
US6613541B1 (en) * 1998-10-20 2003-09-02 Millennium Pharmaceuticals, Inc. Method for monitoring proteasome inhibitor drug action
US6492333B1 (en) * 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US6649593B1 (en) * 1999-10-13 2003-11-18 Tularik Inc. Modulators of SREBP processing
US20040039129A1 (en) * 2000-08-16 2004-02-26 Hall Dennis G. Non-pressurized methods for the preparation of conjugrated solid supports for boronic acids
US6919382B2 (en) 2000-08-31 2005-07-19 The Governors Of The University Of Alberta Preparation and uses of conjugated solid supports for boronic acids
ATE338564T1 (de) * 2000-10-12 2006-09-15 Viromics Gmbh Proteasome inhibitoren zur behandlung von hepatitis-virus infektionen
CA2435124A1 (en) * 2001-01-25 2002-08-01 Millennium Pharmaceuticals, Inc. Formulation of boronic acid compounds
CA2447909C (en) 2001-05-21 2011-04-05 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
US7112588B2 (en) * 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
US6933290B2 (en) 2001-05-30 2005-08-23 Novartis Ag 2-{N-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives
JPWO2003033507A1 (ja) * 2001-10-12 2005-02-03 杏林製薬株式会社 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
JPWO2003033506A1 (ja) * 2001-10-12 2005-02-03 杏林製薬株式会社 アミノボラン酸誘導体およびそれを含有するプロテアソーム阻害薬
US7524883B2 (en) 2002-01-08 2009-04-28 Eisai R&D Management Co., Ltd. Eponemycin and epoxomicin analogs and uses thereof
WO2003077928A1 (en) * 2002-03-12 2003-09-25 Ariad Pharmaceuticals, Inc. Peptide analogues and uses thereof
EA007099B1 (ru) 2002-03-13 2006-06-30 Янссен Фармацевтика Н. В. Сульфонилпроизводные в качестве ингибиторов гистон-деацетилазы
ATE521592T1 (de) 2002-03-13 2011-09-15 Janssen Pharmaceutica Nv Histone-deacetylase-inhibitoren
MXPA04008795A (es) * 2002-03-13 2004-11-26 Janssen Pharmaceutica Nv Derivados de piperazinilo, piperidinilo y morfolino como novedosos inhibidores de la desacetilasa de histona.
US7446109B2 (en) * 2002-03-13 2008-11-04 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
EP1492545B1 (de) * 2002-04-05 2010-09-15 ViroLogik GmbH Mittel zur behandlung von flaviviridae-infektionen
US7514579B2 (en) * 2002-06-13 2009-04-07 Johns Hopkins University Boronic chalcone derivatives and uses thereof
AU2003248921A1 (en) * 2002-07-09 2004-01-23 Point Therapeutics, Inc. Boroproline compound combination therapy
DK1536777T3 (da) * 2002-08-14 2007-06-04 Janssen Pharmaceutica Nv Anvendelse af NF-KB-inhibitorer til behandling af mastitis
US20050119226A1 (en) * 2003-09-09 2005-06-02 Trigen Limited Methods for synthesizing organoboronic compounds and products thereof
US20050176651A1 (en) * 2002-09-09 2005-08-11 Trigen Limited Peptide boronic acids useful in making salts thereof
US7371729B2 (en) * 2002-09-09 2008-05-13 Trigen Limited Boronic acid salts useful in parenteral formulations
EP1396269A1 (en) * 2002-09-09 2004-03-10 Trigen Limited Boronic acid salts of multivalent metals used in the preparation of a medicament for treating thrombosis
US20060084592A1 (en) * 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
US20050282757A1 (en) * 2002-09-09 2005-12-22 Trigen Limited Peptide boronic acid compounds useful in anticoagulation
PL374700A1 (pl) * 2002-09-20 2005-10-31 Alcon, Inc. Zastosowanie inhibitorów syntezy cytokiny do leczenia zespołu suchego oka
ES2542328T3 (es) 2002-12-06 2015-08-04 Millennium Pharmaceuticals, Inc. Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma
CN100341880C (zh) * 2003-02-13 2007-10-10 上海仁虎制药股份有限公司 新型硼酸或硼酸酯类化合物、制备方法及在药学上的应用
US20070110785A1 (en) * 2003-07-03 2007-05-17 Eugene Tedeschi Medical devices with proteasome inhibitors for the treatment of restenosis
US7223745B2 (en) * 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
AU2004288231A1 (en) * 2003-11-05 2005-05-19 Palingen, Inc. Enhanced B cell cytotoxicity of CDIM binding antibody
US20060052390A1 (en) * 2003-12-24 2006-03-09 Scios, Inc. Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
RU2379315C2 (ru) * 2004-02-23 2010-01-20 Трастиз Оф Тафтс Колледж Ингибиторы дипептидилпептидазы iv
GB0405272D0 (en) * 2004-03-09 2004-04-21 Trigen Ltd Compounds
US7371875B2 (en) * 2004-03-12 2008-05-13 Miikana Therapeutics, Inc. Cytotoxic agents and methods of use
AU2016202747B2 (en) * 2004-03-30 2017-11-23 Millennium Pharmaceuticals, Inc. Synthesis of boronic ester and acid compounds
RS65253B1 (sr) * 2004-03-30 2024-03-29 Millennium Pharm Inc Sinteza jedinjenja estra organoborne kiseline i organoborne kiseline
EP1745064B1 (en) 2004-04-15 2011-01-05 Proteolix, Inc. Compounds for proteasome enzyme inhibition
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
CN102875642A (zh) 2004-05-10 2013-01-16 普罗特奥里克斯公司 用于酶抑制的化合物
JP2008504292A (ja) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 免疫増強用の化合物
CN101087756B (zh) 2004-07-23 2011-04-06 纽阿达有限责任公司 肽酶抑制剂
NZ552865A (en) 2004-07-28 2009-09-25 Janssen Pharmaceutica Nv Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
CA2584515A1 (en) 2004-10-20 2006-04-27 Proteolix, Inc. Labeled compounds for proteasome inhibition
WO2006052641A2 (en) 2004-11-05 2006-05-18 Palingen, Inc. Antibody induced cell membrane wounding
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
US20070098685A1 (en) * 2005-01-19 2007-05-03 Brand Stephen J Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
AU2006207325B2 (en) 2005-01-21 2012-08-16 Astex Therapeutics Limited Pharmaceutical compounds
WO2006081371A2 (en) * 2005-01-27 2006-08-03 Research Development Foundation Combination therapy with triterpenoid compounds and proteasome inhibitors
US7468383B2 (en) * 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
PT3424932T (pt) * 2005-02-16 2021-05-19 Anacor Pharmaceuticals Inc Boronoftalidas para utilização terapêutica
US7589066B2 (en) * 2005-03-11 2009-09-15 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
AU2006242446A1 (en) * 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
ES2553178T3 (es) 2005-05-18 2015-12-04 Janssen Pharmaceutica N.V. Derivados sustituidos de aminopropenil piperidina o morfolina como nuevos inhibidores de histona deacetilasa
AU2006202209B2 (en) * 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
PT1888123E (pt) * 2005-06-08 2013-03-13 Janssen Biotech Inc Uma terapêutica celular para a degeneração ocular
WO2007002972A2 (en) * 2005-07-06 2007-01-11 Biodevelops Pharma Entwicklung Gmbh Use of a compound for enhancing the expression of membrane proteins on the cell surface
EP1752467A1 (en) 2005-08-10 2007-02-14 4Sc Ag Inhibitors of cancer cell, t-cell and keratinocyte proliferation
US7531517B2 (en) 2005-08-10 2009-05-12 4Sc Ag Inhibitors of cancer cell, T-cell and keratinocyte proliferation
US20070059382A1 (en) * 2005-09-09 2007-03-15 Board Of Regents, Univ. And Comm. College System Of Nevada... Medical treatment of breast cancer with boric acid materials
ES2628620T3 (es) 2005-11-09 2017-08-03 Onyx Therapeutics, Inc. Compuesto para inhibición de enzimas
US20090221488A1 (en) * 2005-12-08 2009-09-03 Wood Kenneth W Certain Compositions and Methods of Treatment
JP2009526751A (ja) 2005-12-30 2009-07-23 アナコール ファーマシューティカルズ，インコーポレイテッド ホウ素含有小分子
JP5225104B2 (ja) * 2006-01-19 2013-07-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 新しい、ヒストンデアセチラーゼのインヒビターとしてのアミノフェニル誘導体
EP1979327A1 (en) * 2006-01-19 2008-10-15 Janssen Pharmaceutica, N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
DK1979326T3 (da) 2006-01-19 2013-01-07 Janssen Pharmaceutica Nv Pyridin- og pyrimidinderivater som inhibitorer af histondeacetylase
CA2635015C (en) * 2006-01-19 2014-06-03 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
RU2508113C2 (ru) * 2006-02-16 2014-02-27 Анакор Фармасьютикалз, Инк. Борсодержащие малые молекулы в качестве противовоспалительных средств
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
WO2007143600A2 (en) * 2006-06-05 2007-12-13 Incyte Corporation Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
CA2657213C (en) 2006-06-19 2017-01-03 Proteolix, Inc. Peptide epoxyketones for proteasome inhibition
KR101489947B1 (ko) * 2006-09-15 2015-02-04 얀센 파마슈티카 엔.브이. 프로테아좀 억제제와 배합하여, ｉ－형 및 ｉｉｂ－형 히스톤 데아세틸라아제에 결합 활성을 나타내는 히스톤 데아세틸라아제 억제제
MX2009002926A (es) * 2006-09-15 2009-03-31 Janssen Pharmaceutica Nv Combinaciones de inhibidores de histona desacetilasa especificos de clase-i con inhibidores del proteasoma.
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
AU2007221966A1 (en) * 2006-12-08 2008-06-26 Centenary Institute Of Cancer Medicine And Cell Biology Assay for response to proteasome inhibitors
JO3396B1 (ar) * 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
US9080145B2 (en) * 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
US9096832B2 (en) 2007-07-31 2015-08-04 Lifescan, Inc. Differentiation of human embryonic stem cells
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
SI2170396T1 (sl) 2007-08-03 2017-04-26 Summit (Oxford) Limited Kombinacije zdravil za zdravljenje duchennove mišične distrofije
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
AU2016253697A1 (en) * 2007-08-06 2016-11-24 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
KR20140042933A (ko) 2007-08-06 2014-04-07 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아좀 억제제
EA034601B1 (ru) * 2007-08-06 2020-02-25 Милленниум Фармасьютикалз, Инк. Способ получения бороновых кислот
US20100226597A1 (en) * 2007-09-12 2010-09-09 Dr. Reddy's Laboratories Limited Bortezomib and process for producing same
US20090076031A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bortezomib
KR20100088664A (ko) 2007-10-04 2010-08-10 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
US7838673B2 (en) * 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
CN107574142B (zh) * 2007-11-27 2021-07-06 生命扫描有限公司 人胚胎干细胞的分化
CN101220048B (zh) * 2007-12-14 2012-08-15 江苏先声药物研究有限公司 ZnCl2催化下的蒎烷二醇酯的制备方法
UY31545A1 (es) 2007-12-20 2009-08-03 Nuevos derivados de 2-carboxamida cianoaminourea, sus sales y profarmacos farmacéuticamente aceptables, procesos de preparacion y aplicaciones
CA2959401C (en) 2008-02-21 2021-12-07 Centocor Ortho Biotech Inc. Methods, surface modified plates and compositions for cell attachment, cultivation and detachment
KR20150065941A (ko) * 2008-03-06 2015-06-15 아나코르 파마슈티칼스 인코포레이티드 소염제로써 붕소가 함유된 소분자
WO2009140309A2 (en) * 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
EA030685B1 (ru) * 2008-06-17 2018-09-28 Милленниум Фармасьютикалз, Инк. Способ получения соединения боронатного эфира
KR20180018839A (ko) 2008-06-30 2018-02-21 얀센 바이오테크 인코포레이티드 만능 줄기 세포의 분화
CN101638414B (zh) * 2008-07-30 2014-01-08 江苏先声药物研究有限公司 肽硼酸及其酯类化合物、制备方法及其用途
US20100028307A1 (en) * 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
EP2348863A4 (en) * 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
WO2010028005A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
US9493489B2 (en) * 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
US20110236428A1 (en) 2008-10-21 2011-09-29 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
CN102333862B (zh) * 2008-10-31 2018-04-27 詹森生物科技公司 人胚胎干细胞向胰腺内分泌谱系的分化
US9234178B2 (en) 2008-10-31 2016-01-12 Janssen Biotech, Inc. Differentiation of human pluripotent stem cells
ES2584053T3 (es) * 2008-11-20 2016-09-23 Janssen Biotech, Inc. Métodos y composiciones para la unión de células y cultivo en sustratos planos
MX356756B (es) 2008-11-20 2018-06-11 Centocor Ortho Biotech Inc Células madre pluripotentes en microportadores.
CN101747354B (zh) * 2008-12-04 2014-08-13 江苏先声药物研究有限公司 一类β氨基酸组成的二肽硼酸及其酯类化合物、制备方法及其用途
PE20120052A1 (es) * 2008-12-17 2012-02-13 Anacor Pharmaceuticals Inc Polimorfos de (s)-3-amino-metil-7-(3-hidroxi-propoxi)-3h-benzo-[c][1,2]-oxaborol-1-ol
CA2748921A1 (en) 2009-01-09 2010-08-12 Sun Pharma Advanced Research Company Limited Bortezumib containing pharmaceutical composition
US20120190565A1 (en) 2009-02-20 2012-07-26 Pangea Biosciences, Inc. Method Of Diagnosis Or Prognosis Of A Neoplasm Comprising Determining The Level Of Expression Of A Protein In Stromal Cells Adjacent To The Neoplasm
EP2405916B1 (en) 2009-03-12 2018-02-07 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
WO2010106135A1 (en) 2009-03-20 2010-09-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combined use for the treatment of ovarian carcinoma
HRP20150948T1 (hr) 2009-03-24 2015-10-09 Janssen Pharmaceutica N.V. Biomarkeri za procjenjivanje perifernog neuropatskog odgovora na lijeäśenje sa inhibitorom proteazoma
WO2010117668A1 (en) * 2009-03-30 2010-10-14 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
WO2010114768A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-epothilone conjugates, particles, compositions, and related methods of use
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
CA2763471A1 (en) * 2009-05-27 2010-12-02 Cephalon, Inc. Combination therapy for the treatment of multiple myeloma
JP2012530116A (ja) 2009-06-19 2012-11-29 レツク・フアーマシユーテイカルズ・デー・デー 脱ハロゲン化なしにハロゲノアルケンを水素化する方法
EP2270019A1 (en) 2009-06-19 2011-01-05 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters
CN101928329B (zh) * 2009-06-19 2013-07-17 北京大学 三肽硼酸(酯)类化合物、其制备方法和应用
EP2280016A1 (en) 2009-07-27 2011-02-02 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters via substituted alk-1-ynes
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
DE102009027754A1 (de) 2009-07-15 2011-05-05 Schubert, Ulrich, Dr. Verfahren zur Hemmung der Reifung von dendritischen Zellen
KR101785626B1 (ko) * 2009-07-20 2017-10-16 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
WO2011011300A2 (en) 2009-07-20 2011-01-27 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells
JP5819826B2 (ja) 2009-07-20 2015-11-24 ヤンセン バイオテツク，インコーポレーテツド ヒト胚性幹細胞の分化
US8343944B2 (en) * 2009-07-28 2013-01-01 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
WO2011019618A1 (en) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011022502A1 (en) 2009-08-18 2011-02-24 Georgetown University Boronic acid compositions and methods related to cancer
US20110207701A1 (en) * 2009-08-19 2011-08-25 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011029802A1 (en) 2009-09-08 2011-03-17 F. Hoffmann-La Roche Ag 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
US20110124597A1 (en) * 2009-09-25 2011-05-26 Anacor Pharmaceuticals, Inc. Boron containing small molecules
EP2305285A1 (en) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Means and methods for treating ischemic conditions
RS55931B1 (sr) 2009-10-01 2017-09-29 Janssen Pharmaceutica Nv Inhibitori proteazoma za lečenje kancera
WO2011049971A1 (en) 2009-10-20 2011-04-28 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
US20110212918A1 (en) * 2009-11-11 2011-09-01 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
EP2516449A1 (en) 2009-12-22 2012-10-31 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
AU2010333840B2 (en) 2009-12-23 2016-01-07 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
KR101773538B1 (ko) 2009-12-23 2017-08-31 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
WO2011090940A1 (en) 2010-01-19 2011-07-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US8716478B2 (en) 2010-01-27 2014-05-06 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
PH12012501686A1 (en) 2010-03-01 2020-10-19 Janssen Biotech Inc Methods for purifying cells derived from pluripotent stem cells
MX2012010017A (es) * 2010-03-01 2012-10-01 Onyx Therapeutics Inc Compuestos de para la inhibicion de inmunoproteasomas.
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
WO2011116286A2 (en) * 2010-03-18 2011-09-22 Innopharma, Llc Stable bortezomib formulations
US8623911B2 (en) 2010-03-19 2014-01-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agent
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
US8513218B2 (en) * 2010-03-31 2013-08-20 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
AU2013204868B2 (en) * 2010-03-31 2016-10-13 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
MX2012011604A (es) 2010-04-07 2013-02-27 Onyx Therapeutics Inc Inhibidor de inmunoproteasoma de péptido epoxicetona cristalino.
CN101812026B (zh) * 2010-04-12 2013-08-28 亚邦医药股份有限公司 一种硼替佐米的合成方法
CN102946879B (zh) 2010-04-19 2015-04-22 尼基制药公司 一种蛋白酶体抑制剂和镓络合物在制备治疗增殖性疾病的药物中的应用
US8809282B2 (en) 2010-05-06 2014-08-19 Duke University Method of reducing titers of antibodies specific for a therapeutic agent
CN102884176B (zh) 2010-05-12 2017-09-05 詹森生物科技公司 人胚胎干细胞的分化
EP2571525A4 (en) 2010-05-18 2016-04-27 Cerulean Pharma Inc Compositions and methods for treating autoimmune and other diseases
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
AU2011296383B2 (en) 2010-08-31 2016-03-10 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
RU2620938C2 (ru) 2010-08-31 2017-05-30 Янссен Байотек, Инк. Дифференцирование эмбриональных стволовых клеток человека
MX355077B (es) 2010-08-31 2018-04-03 Janssen Biotech Inc Diferenciacion de celulas madre embrionarias humanas.
CN108610356B (zh) 2010-09-07 2021-02-26 阿纳科制药公司 苯并氧杂硼杂环戊二烯衍生物用于治疗细菌感染
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
AU2011312264B2 (en) 2010-10-05 2015-07-02 Fresenius Kabi Usa, Llc Bortezomib formulations stabilised with boric acid
EP2627636B1 (en) 2010-10-14 2015-09-02 Synthon BV Process for making bortezomib and the intermediates for the process
AU2012213080B2 (en) 2011-01-31 2014-03-27 Novartis Ag Novel heterocyclic derivatives
TW201309303A (zh) * 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
US9272014B2 (en) 2011-03-29 2016-03-01 Texas Tech University System Galectin-3C combination therapy for human cancer
RU2569847C2 (ru) 2011-03-31 2015-11-27 Нанокэрриер Ко., Лтд. Фармацевтическая композиция, содержащая блок-сополимер, включающий соединение бороновой кислоты
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
MX2013015308A (es) * 2011-06-22 2014-05-20 Cephalon Inc Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
US8481655B2 (en) 2011-07-27 2013-07-09 Wacker Chemical Corporation Copper complexes of amino-functional organosilicon compounds and their use
WO2013021032A1 (en) 2011-08-11 2013-02-14 Janssen Pharmaceutica Nv Histone deacetylase inhibitors in combination with proteasome inhibitors and dexamethasone
CA2844825A1 (en) 2011-08-11 2013-02-14 Janssen Pharmaceutica Nv Predictors for cancer treatment
EP3199531A1 (en) 2011-08-19 2017-08-02 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis c virus infections
EP4144354B1 (en) 2011-08-30 2025-11-26 Trustees Of Tufts College Fap-activated proteasome inhibitors for treating solid tumors
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
PH12014500912A1 (en) 2011-10-28 2014-06-09 Novartis Ag Novel purine derivatives and their use in the treatment of disease
WO2013063496A1 (en) 2011-10-28 2013-05-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to nae inhibitors
WO2013071142A1 (en) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
JP6286358B2 (ja) 2011-11-11 2018-02-28 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤に応答するバイオマーカー
AU2012337721B2 (en) 2011-11-17 2015-12-10 Nanocarrier Co., Ltd. Block copolymer having phenylboronic acid group introduced therein, and use thereof
US9388386B2 (en) 2011-12-22 2016-07-12 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
WO2013110005A1 (en) 2012-01-18 2013-07-25 Wisconsin Alumni Research Foundation Boronate-mediated delivery of molecules into cells
US9732101B2 (en) 2012-01-18 2017-08-15 Wisconsin Alumni Research Foundation Bioreversible boronates for delivery of molecules into cells
EP2810066B1 (en) 2012-01-24 2019-07-31 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
US10085987B2 (en) 2012-01-27 2018-10-02 Thomas Jefferson University MCT protein inhibitor-related prognostic and therapeutic methods
AU2013200903B2 (en) 2012-02-08 2015-05-14 Mcure Biosciences Inc. CDIM binding proteins and uses thereof
CA2866135A1 (en) 2012-03-02 2014-09-06 Dr. Reddy's Laboratories Limited Pharmaceutical compositions comprising boronic acid compounds
US9434920B2 (en) 2012-03-07 2016-09-06 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
CA2784240C (en) 2012-03-27 2014-07-08 Innopharma, Inc. Stable bortezomib formulations
US10213432B2 (en) 2012-05-16 2019-02-26 Novartis Ag Dosage regimen for a PI-3 kinase inhibitor
CN108103005A (zh) 2012-06-08 2018-06-01 詹森生物科技公司 人胚胎干细胞向胰腺内分泌细胞的分化
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
JP2013006855A (ja) * 2012-09-03 2013-01-10 Millennium Pharmaceuticals Inc プロテアソーム阻害剤
JP2015532915A (ja) * 2012-09-11 2015-11-16 シプラ・リミテッド ボルテゾミブの製造方法
EP2904115B1 (en) 2012-10-01 2018-08-08 Millennium Pharmaceuticals, Inc. Biomarkers and methods to predict response to inhibitors and uses thereof
WO2014072985A1 (en) 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
EP2919786A4 (en) 2012-11-16 2016-06-01 Shilpa Medicare Ltd Crystalline bortezomib process
WO2014097306A1 (en) 2012-12-21 2014-06-26 Natco Pharma Limited Stable and pure polymorphic form of bortezomib
ES2942484T3 (es) 2012-12-31 2023-06-01 Janssen Biotech Inc Diferenciación de células madre embrionarias humanas en células endocrinas pancreáticas usando reguladores de HB9
JP6529440B2 (ja) 2012-12-31 2019-06-12 ヤンセン バイオテツク，インコーポレーテツド 膵内分泌細胞への分化のためのヒト多能性細胞の懸濁及びクラスタリング
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
SG10201709338RA (en) 2012-12-31 2017-12-28 Janssen Biotech Inc Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
MX364895B (es) 2013-03-13 2019-05-10 Forma Therapeutics Inc Nuevos compuestos y composiciones para la inhibicion de fasn.
ZA201402789B (en) 2013-04-16 2015-11-25 Cipla Ltd Process for the preparation of bortezomib mannitol ester
EP2986290A4 (en) 2013-04-19 2017-01-04 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US10478445B2 (en) 2013-07-03 2019-11-19 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
MX2016003979A (es) 2013-10-03 2016-06-15 Millennium Pharm Inc Metodo para profilaxis o tratamiento de lupus eritematoso sistemico y/o nefritis lupica.
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CN104586776B (zh) * 2013-10-30 2017-05-17 扬子江药业集团上海海尼药业有限公司 以硼替佐米为活性成分的制剂及其制备方法
WO2015076359A1 (ja) * 2013-11-21 2015-05-28 国立大学法人北海道大学 プロテアソーム阻害性化合物
US10191033B2 (en) 2013-12-05 2019-01-29 The Broad Institute, Inc. Biomarkers for detecting pre-cachexia or cachexia and methods of treatment thereof
CA2930359C (en) 2013-12-06 2022-03-01 Novartis Ag Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
EP3102585B1 (en) 2014-02-03 2021-05-19 Ohio State Innovation Foundation Boronic acid esters and pharmaceutical formulations thereof
EP2910557A1 (en) * 2014-02-20 2015-08-26 Ikerchem, S.L. Enantiopure tetrasubstituted pyrrolidines as scaffolds for proteasome inhibitors and medicinal applications thereof
WO2015170757A1 (ja) 2014-05-08 2015-11-12 国立大学法人 東京大学 医薬組成物
CN117821369A (zh) 2014-05-16 2024-04-05 詹森生物科技公司 小分子增强胰腺内分泌细胞中的mafa表达的用途
UY36132A (es) 2014-05-20 2015-11-30 Millennium Pharm Inc Métodos para terapia de cáncer
EP3177292B1 (en) 2014-08-07 2020-11-25 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
CN107074885B (zh) * 2014-10-01 2020-11-27 默克专利股份公司 硼酸衍生物
WO2016110870A1 (en) 2015-01-07 2016-07-14 Emcure Pharmaceuticals Limited Pharmaceutical composition of bortezomid
MA41505A (fr) 2015-02-11 2017-12-19 Millennium Pharm Inc Nouvelle forme cristalline d'un inhibiteur de protéasome
US20180243217A1 (en) 2015-03-17 2018-08-30 Leon-Nanodrugs Gmbh Nanoparticles comprising a stabilized boronic acid compound
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
WO2016184793A1 (en) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
WO2016205790A2 (en) 2015-06-19 2016-12-22 Hanlin Scientific, Inc. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
EP3120836A1 (de) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Gebrauchsfertige bortezomib-lösung
EP3120837A1 (de) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Verfahren zur herstellung einer bortezomibester-lösung
CN106478700B (zh) * 2015-08-26 2020-12-29 杭州雷索药业有限公司 硼基取代的苯胺类蛋白激酶抑制剂
CN106588965A (zh) * 2015-10-15 2017-04-26 北京大学 脲拟肽硼酸化合物及其药物组合物、制备方法和用途
CN108472289A (zh) 2015-11-02 2018-08-31 诺华股份有限公司 磷脂酰肌醇3-激酶抑制剂的给药方案
US11111296B2 (en) 2015-12-14 2021-09-07 The Broad Institute, Inc. Compositions and methods for treating cardiac dysfunction
CN107151254A (zh) * 2016-03-06 2017-09-12 复旦大学 一种作为20s蛋白酶体抑制剂的硼酸类化合物及其制备方法
CN107151255A (zh) * 2016-03-06 2017-09-12 复旦大学 硼酸类化合物及其制备方法和用途
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
CN106008572B (zh) * 2016-05-23 2018-08-17 成都千禧莱医药科技有限公司 一类二肽硼酸化合物及制备方法和用途
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
DK3472149T3 (da) 2016-06-21 2023-11-27 Orion Ophthalmology LLC Heterocykliske prolinamidderivater
JP6681284B2 (ja) * 2016-06-23 2020-04-15 信越化学工業株式会社 糖アルコール化合物の金属低減方法
JP6223508B2 (ja) * 2016-06-27 2017-11-01 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
WO2018038687A1 (en) 2016-08-22 2018-03-01 Mustafa Nevzat Ilaç Sanayii A.Ş. Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
US20200261596A1 (en) 2016-10-20 2020-08-20 Pfizer Inc. Therapeutic Particles with Peptide Boronic Acid or Boronate Ester Compounds and Methods of Making and Using Same
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP4046989A1 (en) 2017-01-09 2022-08-24 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2018150386A1 (en) 2017-02-17 2018-08-23 Fresenius Kabi Oncology Ltd. An improved process for the preparation of boronic acid esters
WO2018160717A1 (en) 2017-02-28 2018-09-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
EP3672586A1 (en) 2017-08-23 2020-07-01 Kezar Life Sciences Immunoproteasome inhibitors and immunosuppressive agent in the treatment of autoimmune disorders
CA3075714A1 (en) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
JP2018024694A (ja) * 2017-10-03 2018-02-15 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
MX2020005036A (es) 2017-11-16 2020-08-17 Principia Biopharma Inc Inhibidores de inmunoproteasoma.
MA50906A (fr) 2017-11-16 2020-09-23 Principia Biopharma Inc Inhibiteurs d'immunoprotéasome
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CN111867573A (zh) 2018-01-29 2020-10-30 科诺斯治疗学公司 硼替佐米的瘤内递送
TW202003553A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療癌症之abbv-621與抗癌劑之組合
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
WO2020092395A1 (en) 2018-10-29 2020-05-07 Forma Therapeutics, Inc. SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
CN109824756B (zh) * 2019-03-19 2022-03-22 山东大学 含有4-(苯磺酰基)哌嗪-2-酮的苯丙氨酸衍生物及其制备方法与应用
JP2020079299A (ja) * 2020-02-18 2020-05-28 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
CN114437119B (zh) * 2020-10-30 2024-08-09 苏州开拓药业股份有限公司 一种c-Myc蛋白抑制剂及其制备方法和用途
JP2023553011A (ja) * 2020-12-02 2023-12-20 ホフマン・テクノロジーズ・エルエルシー 非ヒト哺乳動物においてがんを調節するための組成物および方法
EP4242213A4 (en) * 2020-12-10 2024-05-08 Lg Chem, Ltd. BORIC ACID COMPOUND
US11964993B2 (en) 2021-07-03 2024-04-23 Shilpa Pharma Lifesciences Limited Crystalline bortezomib process
EP4134083A1 (en) 2021-08-12 2023-02-15 Extrovis AG Pharmaceutical compositions of bortezomib
CN113957441B (zh) * 2021-10-29 2024-01-02 光华科学技术研究院(广东)有限公司 蚀刻液及其制备方法和应用
KR20250008774A (ko) 2022-05-11 2025-01-15 셀진 코포레이션 T 세포 요법 및 그의 생산과 관련된 방법 및 용도
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
EP4611798A1 (en) 2022-11-02 2025-09-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261868A (en) * 1979-08-08 1981-04-14 Lever Brothers Company Stabilized enzymatic liquid detergent composition containing a polyalkanolamine and a boron compound
US4369183A (en) * 1979-09-06 1983-01-18 Merck & Co., Inc. 2-Pyridyl-1,2-benzisothiazolinone-1,1-dioxides and their use as selective protease inhibitors
US4510130A (en) 1983-05-20 1985-04-09 Genetic Diagnostics Corporation Promoting animal and plant growth with leupeptin
US4537773A (en) 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4537707A (en) * 1984-05-14 1985-08-27 The Procter & Gamble Company Liquid detergents containing boric acid and formate to stabilize enzymes
US4842769A (en) * 1985-07-26 1989-06-27 Colgate-Palmolive Co. Stabilized fabric softening built detergent composition containing enzymes
US4759032A (en) 1987-06-03 1988-07-19 Monsanto Company Electrode seal assembly
US5187157A (en) * 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) * 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) * 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
SE8702550D0 (sv) * 1987-06-18 1987-06-18 Anders Grubb Cysteinproteashemmare
WO1988010265A1 (en) 1987-06-19 1988-12-29 The Regents Of The University Of California A new class of low calorie protein sweeteners
EP0315574A3 (de) * 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US4963655A (en) * 1988-05-27 1990-10-16 Mayo Foundation For Medical Education And Research Boron analogs of amino acid/peptide protease inhibitors
US5106948A (en) * 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) * 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
ZA897514B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
US4997929A (en) * 1989-01-05 1991-03-05 Synergen, Inc. Purified ciliary neurotrophic factor
US4959179A (en) * 1989-01-30 1990-09-25 Lever Brothers Company Stabilized enzymes liquid detergent composition containing lipase and protease
JP2701932B2 (ja) * 1989-04-10 1998-01-21 サントリー株式会社 タンパク質分解酵素阻害剤
US5030378A (en) * 1990-01-02 1991-07-09 The Procter & Gamble Company Liquid detergents containing anionic surfactant, builder and proteolytic enzyme
IL97428A0 (en) 1990-03-05 1992-06-21 Cephalon Inc Chymotrypsin-like proteases and their inhibitors
GB9017694D0 (en) * 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
EP0478050A1 (en) * 1990-09-24 1992-04-01 Unilever N.V. Detergent composition
GB9024129D0 (en) * 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
CA2098609A1 (en) * 1990-12-28 1992-06-29 Raymond T. Bartus Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
JP2703408B2 (ja) 1990-12-28 1998-01-26 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
CA2098702A1 (en) * 1990-12-28 1992-06-29 James C. Powers Peptide ketoamides, ketoacids, and ketoesters
CA2109526C (en) * 1991-04-30 1998-01-20 Dwight M. Peterson Liquid detergents with an aryl boroic acid
ES2085024T3 (es) * 1991-04-30 1996-05-16 Procter & Gamble Detergentes liquidos reforzados con complejo de acido borico-poliol para inhibir la enzima proteolitica.
EP0511456A1 (en) * 1991-04-30 1992-11-04 The Procter & Gamble Company Liquid detergents with aromatic borate ester to inhibit proteolytic enzyme
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
EP0636143B1 (en) * 1992-04-16 1997-09-24 Zeneca Limited Alpha-aminoboronic acid peptides and their use as elastase inhibitors
AU4077193A (en) * 1992-04-16 1993-11-18 Zeneca Limited Alpha-aminoboronic acid peptides and their use as elastase inhibitors
EP0583536B1 (en) * 1992-08-14 1997-03-05 The Procter & Gamble Company Liquid detergents containing an alpha-amino boronic acid
AU676721B2 (en) 1993-02-10 1997-03-20 Dana-Farber Cancer Institute Role of ATP-ubiquitin-dependent proteolysis in MHC-1 restricted antigen presentation and inhibitors thereof
US5384410A (en) * 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
DE4311835A1 (de) * 1993-04-07 1994-10-13 Boehringer Ingelheim Int Verfahren zur Inhibierung der Transkription von Genen
US5424904A (en) * 1993-10-04 1995-06-13 Taylor, Sr.; Thomas T. Circuit for electrically controlled intermittent motion
IL111176A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) * 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US5550262A (en) * 1994-11-14 1996-08-27 Cephalon, Inc. Multicatalytic protease inhibitors
CA2435124A1 (en) * 2001-01-25 2002-08-01 Millennium Pharmaceuticals, Inc. Formulation of boronic acid compounds
RS65253B1 (sr) * 2004-03-30 2024-03-29 Millennium Pharm Inc Sinteza jedinjenja estra organoborne kiseline i organoborne kiseline

Also Published As

Publication number Publication date
NL300151I1 (nl) 2004-08-02
NZ296717A (en) 1999-11-29
EP1312609B1 (en) 2005-12-28
CN1305475C (zh) 2007-03-21
US20150072942A1 (en) 2015-03-12
US20040167332A1 (en) 2004-08-26
CA2203936C (en) 2005-04-12
WO1996013266A1 (en) 1996-05-09
EP0788360B3 (en) 2009-08-12
NL300151I2 (nl) 2004-09-01
ATE411324T1 (de) 2008-10-15
ES2254803T3 (es) 2006-06-16
NZ337211A (en) 2000-12-22
KR970706824A (ko) 1997-12-01
US20110306560A1 (en) 2011-12-15
PT1627880E (pt) 2009-01-23
EP1627880A1 (en) 2006-02-22
AU4139896A (en) 1996-05-23
DK0788360T3 (da) 2003-09-22
US20030199561A1 (en) 2003-10-23
IL115790A (en) 2002-12-01
ES2314540T3 (es) 2009-03-16
CA2496538C (en) 2011-08-02
AU710564C (en) 1996-05-23
DK0788360T5 (da) 2017-09-18
US6617317B1 (en) 2003-09-09
DE122004000025I1 (de) 2004-09-30
US20020173488A1 (en) 2002-11-21
JP3717934B2 (ja) 2005-11-16
CN101077875A (zh) 2007-11-28
CN101077875B (zh) 2011-01-26
IL115790A0 (en) 1996-01-19
US6465433B1 (en) 2002-10-15
US20060122390A1 (en) 2006-06-08
ATE314378T1 (de) 2006-01-15
DE69535866D1 (de) 2008-11-27
LU91083I2 (fr) 2004-08-09
IL137726A (en) 2004-08-31
EP0788360A1 (en) 1997-08-13
DE69530936C5 (de) 2007-02-22
CN1168633A (zh) 1997-12-24
FI114801B (fi) 2004-12-31
US7531526B2 (en) 2009-05-12
ES2199257T7 (es) 2010-03-31
IL137726A0 (en) 2001-10-31
CA2496538A1 (en) 1996-05-09
NO2004004I1 (no) 2004-08-06
DE69534727D1 (de) 2006-02-02
US6083903A (en) 2000-07-04
EP1627880B1 (en) 2008-10-15
IL133831A (en) 2004-03-28
JPH10510245A (ja) 1998-10-06
HK1002059A1 (zh) 1998-07-31
IL133831A0 (en) 2001-04-30
DE69534727T2 (de) 2006-09-14
ES2199257T3 (es) 2004-02-16
US6747150B2 (en) 2004-06-08
FR04C0014I1 (zh) 2004-09-17
FI971746L (fi) 1997-06-06
NO971929D0 (no) 1997-04-25
FI20041415L (fi) 2004-11-03
FI120974B (fi) 2010-05-31
AU710564B2 (en) 1999-09-23
DK1312609T3 (da) 2006-05-15
FI971746A0 (fi) 1997-04-23
DE122004000025I2 (de) 2006-09-07
US20070282100A1 (en) 2007-12-06
US7119080B2 (en) 2006-10-10
KR100398944B1 (ko) 2004-06-04
US6066730A (en) 2000-05-23
HK1087714A1 (zh) 2006-10-20
CH0788360H1 (de) 2006-03-15
PT788360E (pt) 2003-10-31
EP1997823A1 (en) 2008-12-03
DK1627880T3 (da) 2008-12-08
NO310558B1 (no) 2001-07-23
CA2203936A1 (en) 1996-05-09
NO971929L (no) 1997-06-12
US5780454A (en) 1998-07-14
EP0788360A4 (en) 1998-05-06
MX9703063A (es) 1998-07-31
EP0788360B1 (en) 2003-05-28
NO2004004I2 (no) 2007-09-10
DE69530936T2 (de) 2004-02-26
US6297217B1 (en) 2001-10-02
US20080132678A1 (en) 2008-06-05
EP1312609A1 (en) 2003-05-21
LU91083I9 (zh) 2018-12-28
US20090247731A1 (en) 2009-10-01
US8003791B2 (en) 2011-08-23
DE69530936T3 (de) 2010-08-26
PT1312609E (pt) 2006-05-31
US20130310320A1 (en) 2013-11-21
FR04C0014I2 (zh) 2005-05-21
CY2484B1 (en) 2005-06-03
US8378099B2 (en) 2013-02-19
US6548668B2 (en) 2003-04-15
DE69530936D1 (de) 2003-07-03
ATE241631T1 (de) 2003-06-15

Similar Documents

Publication Publication Date Title
TW318850B (zh)
CN111801327B (zh) 苯甲酰胺化合物
CA2994404C (en) Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof
TW449590B (en) New arylglycinamide derivatives, processes for the manufacture thereof and pharmaceutical compositions containing these compounds
TW201141480A (en) Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
US20040167337A1 (en) 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives
JP4144811B2 (ja) ペプチジル−２−アミノ−１−ヒドロキシアルカンスルホン酸システインプロテアーゼインヒビター
JP6532515B2 (ja) 新規な含窒素化合物もしくはその塩またはそれらと金属との錯体
AU621041B2 (en) Beta-aminoethyl-substituted compounds and halo- azido- and phthalimido-ethyl-substituted phenyl intermediates
JP2017512812A (ja) 複素環によって構成されるトリペプチドエポキシケトン化合物、並びにその作製方法及び使用
JP2000517305A (ja) Ｎ―［ｎ―ｎ―（４―（ピペリジン―４―イル）ブタノイル）―ｎ―エチルグリシル］化合物の安定な非吸湿性結晶形
JP7658627B2 (ja) ホウ素中性子捕捉療法用の腫瘍組織を短時間で選択的ないし局所的に標的化できる集積性ボロン１０薬剤
JPH06504301A (ja) キレート化剤
EP2651917A1 (en) Dimeric iap inhibitors
EP1896086A1 (en) Hydrazide conjugates as imaging agents
WO2011106721A1 (en) Flurbiprofen analogs and methods of use in treating cancer
CN114126616A (zh) Bcl-2抑制剂的纳米颗粒制剂
JPS58188809A (ja) チアモルホリノン又はその誘導体を含有する皮膚用組成物
CA2405871A1 (en) 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives
WO2005027856A2 (en) Inhibitors of anthrax lethal factor
JPS5951218A (ja) 製薬法および製薬組成物
US3804820A (en) N-(substituted-alpha-penicilloyl)-amino carboxylic acids
JPH0651677B2 (ja) ジペプチド誘導体及びその製法並びに用途
JPS63270663A (ja) ピリジルアルキルアミンのアルキルカルボキシアミド類、その製造及び医薬組成物
Bouanga Boudiombo et al. Solvates of selected fenamic acids with substituted pyridines: structure, thermal stability and desolvation

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent